National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 1) (No. PB 4 of 2014)

Link to law: https://www.comlaw.gov.au/Details/F2014L00098

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 4 of 2014
National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 1)
 
National Health Act 1953
___________________________________________________________________________
 
 
I, LAURA TOYNE, Acting Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the
National Health Act 1953.
Dated   23 January 2014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LAURA TOYNE
Acting Assistant Secretary
Pharmaceutical Access Branch
Pharmaceutical Benefits Division
Department of Health
___________________________________________________________________________
 
 
1       Name of Instrument
 
(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No.1).
 
(2)                This Instrument may also be cited as PB 4 of 2014.
 
2              Commencement
This Instrument commences on 1 February 2014.
3              Amendments to PB 116 of 2010
Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).
 
 
Schedule 1       Amendments
Section 3
[1]     Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 15 mg in 5 mL with manner of administration Injection and brand Pamisol
          Omit from the column headed ‘Circumstances’: C1500 C3341               Substitute: C4430 C4433
[2]     Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 30 mg in 10 mL with manner of administration Injection and brand Pamisol
          Omit from the column headed ‘Circumstances’: C1500 C3341               Substitute: C4424 C4425
[3]     Schedule 1, entry for Pamidronic Acid in the form Injection set containing 2 vials powder for I.V. infusion containing disodium pamidronate 30 mg and 2 ampoules solvent 10 mL manner of administration Injection and brand Aredia 30mg
          Omit from the column headed ‘Circumstances’: C1500 C3341              Substitute: C4424 C4425
[4]     Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 60 mg in 10 mL with manner of administration Injection and brand Pamisol
          Omit from the column headed ‘Circumstances’: C1500 C3341               Substitute: C4430 C4433
[5]     Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 90 mg in 10 mL with manner of administration Injection and brand Pamisol
          Omit from the column headed ‘Circumstances’: C1035 C1233 C1500 C3341 C3342 C3343
          Substitute: C4421 C4426 C4428 C4429 C4431 C4432
 
[6]     Schedule 1, entry for Pamidronic Acid in the form Injection set containing 1 vial powder for I.V. infusion containing disodium pamidronate 90 mg and 1 ampoule solvent 10 mL manner of administration Injection and brand Aredia 90mg
          Omit from the column headed ‘Circumstances’: C1035 C1233 C1500 C3341 C3342 C3343
Substitute: C4421 C4426 C4428 C4429 C4431 C4432
[7]     Schedule 3, entry for Pamidronic Acid
 
          Substitute:

Pamidronic Acid
C4421
 
 
Where the patient is receiving treatment at/from a public hospital
Hypercalcaemia of malignancy
Patient must have a malignancy refractory to anti-neoplastic therapy
Compliance with Written and Telephone Authority Required procedures –  Streamlined Authority Code 4421

 
C4424
 
 
Where the patient is receiving treatment at/from a private hospital
Hypercalcaemia of malignancy
Patient must have a malignancy refractory to anti-neoplastic therapy
Compliance with Written and Telephone Authority Required procedures

 
C4425
 
 
Where the patient is receiving treatment at/from a public hospital
Hypercalcaemia of malignancy
Patient must have a malignancy refractory to anti-neoplastic therapy
Compliance with Written and Telephone Authority Required procedures –  Streamlined Authority Code 4425

 
C4426
 
 
Where the patient is receiving treatment at/from a public hospital
Bone metastases
The condition must be due to breast cancer
Compliance with Written and Telephone Authority Required procedures – Streamlined Authority Code 4426

 
C4428
 
 
Where the patient is receiving treatment at/from a private hospital
Hypercalcaemia of malignancy
Patient must have a malignancy refractory to anti-neoplastic therapy
Compliance with Written and Telephone Authority Required procedures

 
C4429
 
 
Where the patient is receiving treatment at/from a private hospital
Bone metastases
The condition must be due to breast cancer
Compliance with Written and Telephone Authority Required procedures

 
C4430
 
 
Where the patient is receiving treatment at/from a private hospital
Hypercalcaemia of malignancy
Patient must have a malignancy refractory to anti-neoplastic therapy
Compliance with Written and Telephone Authority Required procedures

 
C4431
 
 
Where the patient is receiving treatment at/from a private hospital
Multiple myeloma
Compliance with Written and Telephone Authority Required procedures

 
C4432
 
 
Where the patient is receiving treatment at/from a public hospital
Multiple myeloma
Compliance with Written and Telephone Authority Required procedures – Streamlined Authority Code 4432

 
C4433
 
 
Where the patient is receiving treatment at/from a public hospital
Hypercalcaemia of malignancy
Patient must have a malignancy refractory to anti-neoplastic therapy
Compliance with Written and Telephone Authority Required procedures –  Streamlined Authority Code 4433